Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo

Molecular Carcinogenesis
Yuanfei ShiBing Xu

Abstract

The bromodomain and extra-terminal (BET) domain inhibitor JQ1 exerts potent anticancer activity in various cancer cells. However, the resistance to BET inhibitors in leukemia stem cells limits its implication in acute myeloid leukemia (AML). High concentration of triptolide (TPL) presents anticancer activities but with adverse effects. Here, we investigated whether the combination of low-dose TPL with JQ1 could help to circumvent the dilemma of drug resistance and side effect in treating AML. AML cell lines, primary cells from 10 AML patients with different status, as well as AML mice model were subjected to different treatments and apoptotic related protein expression were evaluated. Data showed that low-dose TPL combined with JQ1 effectively killed AML cell lines and primary cells from AML patients without exerting significantly greater lethal activity against normal cells. Mechanism study revealed that low-dose TPL combined with JQ1 triggered reactive oxygen species production and induced mitochondrial-mediated apoptosis in AML cells, in which the inhibition of RNA polymerase II to downregulate c-Myc was mainly responsible for the enhanced activity of TPL in combination with JQ1. In vivo study presented that cotreatment with...Continue Reading

References

Feb 14, 2006·Science·Saquib A LakhaniRichard A Flavell
Jul 3, 2008·Cancer Research·Stephanie J Leuenroth, Craig M Crews
Oct 20, 2010·Drug and Chemical Toxicology·Jing LiuLuyong Zhang
Feb 1, 2011·Nature Chemical Biology·Denis V TitovJun O Liu
Aug 5, 2011·Nature·Johannes ZuberChristopher R Vakoc
Jul 10, 2014·Leukemia·R B Walter, E H Estey
Jul 25, 2014·European Journal of Pharmacology·Shaloam Dasari, Paul Bernard Tchounwou
Feb 12, 2015·Cancer Cell·Paul T Schumacker
Sep 15, 2015·Nature·Chun Yew FongMark A Dawson
Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Aug 9, 2017·Recent Patents on Anti-cancer Drug Discovery·Imran AliKwangho Lee
Mar 11, 2018·Journal of Experimental & Clinical Cancer Research : CR·Shu-Guang LiWen-Xing Qin
May 10, 2018·Nature Reviews. Molecular Cell Biology·Fei Xavier ChenAli Shilatifard
Dec 12, 2018·Cancer Cell·Delphine MerinoAndreas Strasser
Oct 23, 2019·Nature Reviews. Molecular Cell Biology·Florian J Bock, Stephen W G Tait

❮ Previous
Next ❯

Citations

Oct 3, 2020·Molecular Carcinogenesis

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.